FDA Drug Safety Communication: Avandia (rosiglitazone) labels now contain updated information about cardiovascular risks and use in certain patients

[2-03-2011] The U.S. Food and Drug Administration (FDA) is notifying the public that information on the cardiovascular risks (including heart attack) of the diabetes drug rosiglitazone has been added to the physician labeling and patient Medication Guide.

Source: FDA Center for Drug Evaluation and Research - What's New - June 18, 2019 Category: Drugs & Pharmacology Authors: FDA Source Type: news